| 2025-12-16 |
详情>>
内部人交易：
Horn Margaret A等共交易4笔
|
| 2025-11-05 |
详情>>
股本变动：
变动后总股本19331.98万股
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-4.06美元,归母净利润-7.66亿美元,同比去年增长-88.99%
|
| 2025-11-05 |
财报披露：
美东时间 2025-11-05 盘后发布财报
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益-2.45美元,归母净利润-4.61亿美元,同比去年增长-85.05%
|
| 2025-05-07 |
详情>>
业绩披露：
2025年一季报每股收益-1.13美元,归母净利润-2.13亿美元,同比去年增长-83.97%
|
| 2025-04-29 |
股东大会：
将于2025-06-26召开股东大会
会议内容 ▼▲
- 1.To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified;
2.To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;
3.To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (“Say-on-Pay”);
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-02-26 |
详情>>
业绩披露：
2022年年报每股收益-3.08美元,归母净利润-2.49亿美元,同比去年增长-32.93%
|
| 2025-02-26 |
详情>>
业绩披露：
2024年年报每股收益-3.58美元,归母净利润-6亿美元,同比去年增长-37.52%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.45美元,归母净利润-4.06亿美元,同比去年增长-47.55%
|
| 2024-08-07 |
详情>>
业绩披露：
2023年中报每股收益-1.65美元,归母净利润-1.66亿美元,同比去年增长-39.98%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-1.51美元,归母净利润-2.49亿美元,同比去年增长-49.78%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.7美元,归母净利润-1.16亿美元,同比去年增长-70.35%
|
| 2024-04-25 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their respective successors are elected and qualified.
2.To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
3.To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (“Say-on-Pay”).
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-02-26 |
详情>>
业绩披露：
2023年年报每股收益-3.86美元,归母净利润-4.36亿美元,同比去年增长-75.46%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.65美元,归母净利润-2.75亿美元,同比去年增长-42.99%
|
| 2023-09-29 |
股东大会：
将于2023-11-08召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of shares of Revolution Medicines common stock (including securities convertible into or exercisable for shares of Revolution Medicines common stock) to certain equityholders of EQRx, Inc., which is referred to as EQRx, pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (as it may be amended from time to time), by and among Revolution Medicines, Equinox Merger Sub I, Inc., a wholly owned subsidiary of Revolution Medicines, Equinox Merger Sub II LLC, a wholly owned subsidiary of Revolution Medicines, and EQRx, which is referred to as the merger agreement, a copy of which is included as Annex A to the accompanying joint proxy statement/prospectus, which proposal is referred to as the Revolution Medicines share issuance proposal;
2.To approve the adjournment of the Revolution Medicines special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Revolution Medicines special meeting to approve the Revolution Medicines share issuance proposal, which proposal is referred to as the Revolution Medicines adjournment proposal.
|
| 2023-04-26 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to hold office until the 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified;
2.To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023;
3.To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (“Say-on-Pay”);
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-26 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors to hold office until the 2025 annual meeting of stockholders or until their successors are elected and qualified;
2.To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022;
3.To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (“Say-on-Pay”);
4.To approve, on a non-binding, advisory basis, whether a Say-on-Pay vote should occur every one year, every two years or every three years;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-06-22召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to hold office until the 2024 annual meeting of stockholders or until his or her successor is elected;
2.To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021;
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-08-01 |
复牌提示：
2020-07-31 14:37:04 停牌，复牌日期 2020-07-31 14:42:04
|